Regression of Established Cardiac Fibrosis in Hypertensive Heart Disease

Area of Science:

• Cardiology
• Hypertension Research
• Fibrosis Studies

Background:

• Established cardiac fibrosis (ECF) is prevalent in patients with heart failure with preserved ejection fraction (HFpEF) and hypertension.
• ECF contributes to myocardial stiffness and symptomatic heart failure, representing a significant clinical challenge.
• Current therapeutic strategies for ECF regression in this population are limited.

Purpose of the Study:

• To review the feasibility of regressing ECF in hypertensive heart disease.
• To investigate the cellular and molecular signaling pathways involved in ECF regression.
• To identify knowledge gaps crucial for advancing therapeutic interventions.

Main Methods:

• This is a review article, synthesizing existing research on cardiac fibrosis and hypertension.
• Literature search focused on studies investigating ECF regression, myocardial stiffness, and HFpEF.
• Analysis of cellular and molecular mechanisms implicated in fibrotic remodeling.

Main Results:

• The review suggests that ECF regression in hypertensive heart disease is potentially feasible.
• Key signaling pathways involved in fibrosis and its potential reversal are discussed.
• Significant knowledge gaps remain regarding effective therapeutic strategies.

Conclusions:

• Reversing ECF in hypertensive heart disease could improve myocardial stiffness and HFpEF symptoms.
• Further research into specific cellular/molecular targets is necessary.
• Translational studies are needed to develop effective treatments for ECF regression.